Nippon India Pharma Fund Achieving 50.61% 1 Year Compounded Annual Growth

The Nippon India Pharma Fund has demonstrated strong performance, particularly over the past year, with a 1-year CAGR of 50.61%. Its focus on the pharmaceutical sector has yielded substantial returns, outperforming its benchmarks S&P BSE Healthcare TRI and S&P BSE Sensex TRI over various periods. 

Nippon India Pharma Fund – Performance

Advertisement

  • Latest NAV (as of 04 June 2024): ₹425.66

Overview

Period Nippon India Pharma Fund B: S&P BSE Healthcare TRI AB: S&P BSE Sensex TRI
1 Year CAGR % 50.61% 54.16% 23.23%
3 Year CAGR % 15.71% 15.32% 16.52%
5 Year CAGR % 22.71% 20.60% 15.13%
Since Inception % 20.77% 15.69% 16.25%

Nippon India Pharma Fund – Returns Analysis

Period Invested For ₹10,000 Invested On Latest Value Absolute Returns Annualised Returns Category Avg Rank Within Category
1 Week 28-May-24 ₹9,772.70 -2.27% -3.86% 44/182
1 Month 03-May-24 ₹9,886.70 -1.13% -1.63% 83/181
3 Month 04-Mar-24 ₹9,978.60 -0.21% 1.57% 113/176
6 Month 04-Dec-23 ₹11,247.10 12.47% 14.60% 86/165
YTD 01-Jan-24 ₹10,794.80 7.95% 9.20% 84/169
1 Year 02-Jun-23 ₹14,409.50 44.09% 43.67% 37.62% 46/145
2 Year 03-Jun-22 ₹16,148.40 61.48% 26.99% 26.12% 47/133
3 Year 04-Jun-21 ₹14,465.80 44.66% 13.08% 18.61% 83/121
5 Year 04-Jun-19 ₹29,640.70 196.41% 24.24% 18.94% 18/101
10 Year 04-Jun-14 ₹48,832.80 388.33% 17.17% 14.89% 17/78
Since Inception 05-Jun-04 ₹4,25,668.60 4,156.69% 20.62% 17.14% 45/179

Nippon India Pharma Fund – Portfolio Analysis 

Sector Allocation

The Nippon India Pharma Fund predominantly invests in domestic equities within the pharmaceutical sector.

Investment Type Allocation (%)
Equity 96.17%
Debt 0%
Others 3.83%

Equity Holdings Breakdown

Market Cap Allocation (%)
Large Cap Stocks 41.18%
Mid Cap Stocks 25.33%
Small Cap Stocks 8.85%
Other 20.81%

Nippon India Pharma Fund – Top 10 Stocks

Stock Sector Value (Mn) % of Total Holdings 1M Change 1Y Highest Holding 1Y Lowest Holding Quantity 1M Change in Qty
Sun Pharmaceutical Industries Ltd. Pharmaceuticals 9848.3 13.81% -1.10% 14.91% (Mar 2024) 12.76% (Dec 2023) 65.56 L 0.00
Lupin Ltd. Pharmaceuticals 6095.9 8.55% 0.15% 8.55% (Apr 2024) 7.06% (May 2023) 37.04 L 0.00
Cipla Ltd. Pharmaceuticals 4340.0 6.08% -0.43% 6.8% (Aug 2023) 5.97% (Dec 2023) 31.00 L 0.00
Apollo Hospitals Enterprises Ltd. Hospital 3858.5 5.41% -0.38% 5.98% (Jan 2024) 3.59% (Aug 2023) 6.49 L 0.00
Divis Laboratories Ltd. Pharmaceuticals 3605.4 5.05% 0.69% 5.29% (May 2023) 4.29% (Oct 2023) 9.01 L 0.00
Dr. Reddys Laboratories Ltd. Pharmaceuticals 3412.6 4.78% 0.03% 5.75% (Jul 2023) 4.75% (Mar 2024) 5.50 L 0.00
Gland Pharma Ltd. Pharmaceuticals 2909.0 4.08% -0.32% 5.06% (Dec 2023) 2.43% (May 2023) 17.00 L 0.00
J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceuticals 2642.3 3.70% 0.26% 3.9% (Sep 2023) 3.26% (Feb 2024) 13.87 L -1.00 L
Zydus Lifesciences Ltd. Pharmaceuticals 2575.2 3.61% -0.57% 4.18% (Mar 2024) 3.2% (Dec 2023) 27.01 L -2.53 L
Abbott India Ltd. Pharmaceuticals 2284.7 3.20% -0.09% 3.64% (May 2023) 2.7% (Dec 2023) 86.39 k 0.00

Nippon India Pharma Fund – Risk Ratios

Ratio Value Category Average
Standard Deviation 12.56 (Low volatility) 14.34
Beta 0.89 (High volatility) 0.86
Sharpe Ratio 0.56 (Poor risk-adjusted returns) 0.84
Treynor’s Ratio 0.08 (Poor risk-adjusted returns) 0.14
Jensen’s Alpha 1.22 (Poor risk-adjusted returns) 2.3

Suitable For

Investors with advanced knowledge of macro trends prefer to take selective bets for higher returns compared to other equity funds. These investors should be prepared for the possibility of moderate to high losses in their investments, even if the overall market is performing better.

Disclaimer: The information provided in this article is for educational and informational purposes only. It should not be considered investment advice or a recommendation to invest in any particular mutual fund or asset class. Past performance does not indicate future results, and investors should research and consult with a financial advisor before making investment decisions. Investing in mutual funds involves risks, including the possible loss of principal invested.

Note: Data as on June 5, 2024